1
|
Park SS, Uzelac A, Kotsopoulos J. Delineating the role of osteoprotegerin as a marker of breast cancer risk among women with a BRCA1 mutation. Hered Cancer Clin Pract 2022; 20:14. [PMID: 35418083 PMCID: PMC9008947 DOI: 10.1186/s13053-022-00223-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2021] [Accepted: 03/30/2022] [Indexed: 11/26/2022] Open
Abstract
Women with a pathogenic germline mutation in the BRCA1 gene face a very high lifetime risk of developing breast cancer, estimated at 72% by age 80. Prophylactic bilateral mastectomy is the only effective way to lower their risk; however, most women with a mutation opt for intensive screening with annual MRI and mammography. Given that the BRCA1 gene was identified over 20 years ago, there is a need to identify a novel non-surgical approach to hereditary breast cancer prevention. Here, we provide a review of the emerging preclinical and epidemiologic evidence implicating the dysregulation of progesterone-mediated receptor activator of nuclear factor κB (RANK) signaling in the pathogenesis of BRCA1-associated breast cancer. Experimental studies have demonstrated that RANK inhibition suppresses Brca1-mammary tumorigenesis, suggesting a potential target for prevention. Data from studies conducted among women with a BRCA1 mutation further support this pathway in BRCA1-associated breast cancer development. Progesterone-containing (but not estrogen-alone) hormone replacement therapy is associated with an increased risk of breast cancer in women with a BRCA1 mutation. Furthermore, BRCA1 mutation carriers have significantly lower levels of circulating osteoprotegerin (OPG), the decoy receptor for RANK-ligand (RANKL) and thus endogenous inhibitor of RANK signaling. OPG levels may be associated with the risk of disease, suggesting a role of this protein as a potential biomarker of breast cancer risk. This may improve upon current risk prediction models, stratifying women at the highest risk of developing the disease, and further identify those who may be targets for anti-RANKL chemoprevention. Collectively, the evidence supports therapeutic inhibition of the RANK pathway for the primary prevention of BRCA1-associated breast cancer, which may generate unique prevention strategies (without prophylactic surgery) and enhance quality of life.
Collapse
Affiliation(s)
- Sarah Sohyun Park
- Department of Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada
- Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada
| | - Aleksandra Uzelac
- Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada
- Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada
| | - Joanne Kotsopoulos
- Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada.
- Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
| |
Collapse
|
2
|
Corso PFCDL, Meger MN, Petean IBF, Souza JFD, Brancher JA, da Silva LAB, Rebelatto NLB, Kluppel LE, Sousa-Neto MD, Küchler EC, Scariot R. Examination of OPG, RANK, RANKL and HIF1A polymorphisms in temporomandibular joint ankylosis patients. J Craniomaxillofac Surg 2019; 47:766-770. [DOI: 10.1016/j.jcms.2019.01.024] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2018] [Revised: 12/13/2018] [Accepted: 01/14/2019] [Indexed: 02/05/2023] Open
|
3
|
|
4
|
Kwan JSH, Hsu YH, Cheung CL, Dupuis J, Saint-Pierre A, Eriksson J, Handelman SK, Aragaki A, Karasik D, Pramstaller PP, Kooperberg C, Lacroix AZ, Larson MG, Lau KS, Lorentzon M, Pichler I, Sham PC, Taliun D, Vandenput L, Kiel DP, Hicks AA, Jackson RD, Ohlsson C, Benjamin EJ, Kung AWC. Meta-analysis of genome-wide association studies identifies two loci associated with circulating osteoprotegerin levels. Hum Mol Genet 2014; 23:6684-93. [PMID: 25080503 PMCID: PMC4240210 DOI: 10.1093/hmg/ddu386] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2014] [Revised: 07/14/2014] [Accepted: 07/21/2014] [Indexed: 01/08/2023] Open
Abstract
Osteoprotegerin (OPG) is involved in bone homeostasis and tumor cell survival. Circulating OPG levels are also important biomarkers of various clinical traits, such as cancers and atherosclerosis. OPG levels were measured in serum or in plasma. In a meta-analysis of genome-wide association studies in up to 10 336 individuals from European and Asian origin, we discovered that variants >100 kb upstream of the TNFRSF11B gene encoding OPG and another new locus on chromosome 17q11.2 were significantly associated with OPG variation. We also identified a suggestive locus on chromosome 14q21.2 associated with the trait. Moreover, we estimated that over half of the heritability of OPG levels could be explained by all variants examined in our study. Our findings provide further insight into the genetic regulation of circulating OPG levels.
Collapse
Affiliation(s)
| | - Yi-Hsiang Hsu
- Institute for Aging Research, Hebrew SeniorLife, Boston, MA, USA, Program of Quantitative Genomics, Harvard School of Public Health, Boston, MA, USA, BROAD Institute of the MIT and Harvard, Cambridge, MA, USA
| | | | - Josée Dupuis
- Framingham Heart Study of the National, Heart, Lung, and Blood Institute and Boston University, Framingham, MA, USA, Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA
| | - Aude Saint-Pierre
- Center for Biomedicine, European Academy Bozen/Bolzano (EURAC), Bolzano, Italy - Affiliated Institute of the University of Lübeck, Lübeck, Germany, INSERM U1078, Etablissement Français du Sang, Brest, France
| | - Joel Eriksson
- Centre for Bone and Arthritis Research, Departments of Internal Medicine and Geriatrics, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | | | - Aaron Aragaki
- Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, The Ohio State University, Columbus, OH, USA
| | - David Karasik
- Institute for Aging Research, Hebrew SeniorLife, Boston, MA, USA
| | - Peter P Pramstaller
- Center for Biomedicine, European Academy Bozen/Bolzano (EURAC), Bolzano, Italy - Affiliated Institute of the University of Lübeck, Lübeck, Germany, Department of Neurology, General Central Hospital, Bolzano, Italy, Department of Neurology, University of Lübeck, Lübeck, Germany
| | | | - Andrea Z Lacroix
- Department of Preventive Medicine, University of California San Diego, San Diego, CA, USA
| | - Martin G Larson
- Framingham Heart Study of the National, Heart, Lung, and Blood Institute and Boston University, Framingham, MA, USA, Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA
| | | | - Mattias Lorentzon
- Centre for Bone and Arthritis Research, Departments of Internal Medicine and Geriatrics, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Irene Pichler
- Center for Biomedicine, European Academy Bozen/Bolzano (EURAC), Bolzano, Italy - Affiliated Institute of the University of Lübeck, Lübeck, Germany
| | - Pak C Sham
- Department of Psychiatry and Centre for Genomic Sciences, University of Hong Kong, Pokfulam, Hong Kong
| | - Daniel Taliun
- Center for Biomedicine, European Academy Bozen/Bolzano (EURAC), Bolzano, Italy - Affiliated Institute of the University of Lübeck, Lübeck, Germany
| | - Liesbeth Vandenput
- Centre for Bone and Arthritis Research, Departments of Internal Medicine and Geriatrics, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Douglas P Kiel
- Institute for Aging Research, Hebrew SeniorLife, Boston, MA, USA, BROAD Institute of the MIT and Harvard, Cambridge, MA, USA, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
| | - Andrew A Hicks
- Center for Biomedicine, European Academy Bozen/Bolzano (EURAC), Bolzano, Italy - Affiliated Institute of the University of Lübeck, Lübeck, Germany
| | - Rebecca D Jackson
- Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, The Ohio State University, Columbus, OH, USA
| | - Claes Ohlsson
- Centre for Bone and Arthritis Research, Departments of Internal Medicine and Geriatrics, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Emelia J Benjamin
- Framingham Heart Study of the National, Heart, Lung, and Blood Institute and Boston University, Framingham, MA, USA, Department of Medicine, Boston University School of Medicine, Boston, MA, USA and
| | | |
Collapse
|
5
|
Martin LJ, Pilipenko V, Kaufman KM, Cripe L, Kottyan LC, Keddache M, Dexheimer P, Weirauch MT, Benson DW. Whole exome sequencing for familial bicuspid aortic valve identifies putative variants. ACTA ACUST UNITED AC 2014; 7:677-83. [PMID: 25085919 DOI: 10.1161/circgenetics.114.000526] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
BACKGROUND Bicuspid aortic valve (BAV) is the most common congenital cardiovascular malformation. Although highly heritable, few causal variants have been identified. The purpose of this study was to identify genetic variants underlying BAV by whole exome sequencing a multiplex BAV kindred. METHODS AND RESULTS Whole exome sequencing was performed on 17 individuals from a single family (BAV=3; other cardiovascular malformation, 3). Postvariant calling error control metrics were established after examining the relationship between Mendelian inheritance error rate and coverage, quality score, and call rate. To determine the most effective approach to identifying susceptibility variants from among 54 674 variants passing error control metrics, we evaluated 3 variant selection strategies frequently used in whole exome sequencing studies plus extended family linkage. No putative rare, high-effect variants were identified in all affected but no unaffected individuals. Eight high-effect variants were identified by ≥2 of the commonly used selection strategies; however, these were either common in the general population (>10%) or present in the majority of the unaffected family members. However, using extended family linkage, 3 synonymous variants were identified; all 3 variants were identified by at least one other strategy. CONCLUSIONS These results suggest that traditional whole exome sequencing approaches, which assume causal variants alter coding sense, may be insufficient for BAV and other complex traits. Identification of disease-associated variants is facilitated by the use of segregation within families.
Collapse
Affiliation(s)
- Lisa J Martin
- From the Department of Pediatrics, Cincinnati Children's Hospital Medical Center, OH (L.J.M., V.P., K.M.K., L.C.K., M.K., P.D., M.T.W.); Department of Pediatrics, University of Cincinnati School of Medicine, Cincinnati OH (L.J.M., K.M.K., M.K., M.T.W.); Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University, Columbus (L.C.); Herma Heart Center, Children's Hospital of Wisconsin, Milwaukee (D.W.B.); and Department of Pediatrics, Medical College of Wisconsin, Milwaukee (D.W.B.).
| | - Valentina Pilipenko
- From the Department of Pediatrics, Cincinnati Children's Hospital Medical Center, OH (L.J.M., V.P., K.M.K., L.C.K., M.K., P.D., M.T.W.); Department of Pediatrics, University of Cincinnati School of Medicine, Cincinnati OH (L.J.M., K.M.K., M.K., M.T.W.); Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University, Columbus (L.C.); Herma Heart Center, Children's Hospital of Wisconsin, Milwaukee (D.W.B.); and Department of Pediatrics, Medical College of Wisconsin, Milwaukee (D.W.B.)
| | - Kenneth M Kaufman
- From the Department of Pediatrics, Cincinnati Children's Hospital Medical Center, OH (L.J.M., V.P., K.M.K., L.C.K., M.K., P.D., M.T.W.); Department of Pediatrics, University of Cincinnati School of Medicine, Cincinnati OH (L.J.M., K.M.K., M.K., M.T.W.); Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University, Columbus (L.C.); Herma Heart Center, Children's Hospital of Wisconsin, Milwaukee (D.W.B.); and Department of Pediatrics, Medical College of Wisconsin, Milwaukee (D.W.B.)
| | - Linda Cripe
- From the Department of Pediatrics, Cincinnati Children's Hospital Medical Center, OH (L.J.M., V.P., K.M.K., L.C.K., M.K., P.D., M.T.W.); Department of Pediatrics, University of Cincinnati School of Medicine, Cincinnati OH (L.J.M., K.M.K., M.K., M.T.W.); Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University, Columbus (L.C.); Herma Heart Center, Children's Hospital of Wisconsin, Milwaukee (D.W.B.); and Department of Pediatrics, Medical College of Wisconsin, Milwaukee (D.W.B.)
| | - Leah C Kottyan
- From the Department of Pediatrics, Cincinnati Children's Hospital Medical Center, OH (L.J.M., V.P., K.M.K., L.C.K., M.K., P.D., M.T.W.); Department of Pediatrics, University of Cincinnati School of Medicine, Cincinnati OH (L.J.M., K.M.K., M.K., M.T.W.); Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University, Columbus (L.C.); Herma Heart Center, Children's Hospital of Wisconsin, Milwaukee (D.W.B.); and Department of Pediatrics, Medical College of Wisconsin, Milwaukee (D.W.B.)
| | - Mehdi Keddache
- From the Department of Pediatrics, Cincinnati Children's Hospital Medical Center, OH (L.J.M., V.P., K.M.K., L.C.K., M.K., P.D., M.T.W.); Department of Pediatrics, University of Cincinnati School of Medicine, Cincinnati OH (L.J.M., K.M.K., M.K., M.T.W.); Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University, Columbus (L.C.); Herma Heart Center, Children's Hospital of Wisconsin, Milwaukee (D.W.B.); and Department of Pediatrics, Medical College of Wisconsin, Milwaukee (D.W.B.)
| | - Phillip Dexheimer
- From the Department of Pediatrics, Cincinnati Children's Hospital Medical Center, OH (L.J.M., V.P., K.M.K., L.C.K., M.K., P.D., M.T.W.); Department of Pediatrics, University of Cincinnati School of Medicine, Cincinnati OH (L.J.M., K.M.K., M.K., M.T.W.); Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University, Columbus (L.C.); Herma Heart Center, Children's Hospital of Wisconsin, Milwaukee (D.W.B.); and Department of Pediatrics, Medical College of Wisconsin, Milwaukee (D.W.B.)
| | - Matthew T Weirauch
- From the Department of Pediatrics, Cincinnati Children's Hospital Medical Center, OH (L.J.M., V.P., K.M.K., L.C.K., M.K., P.D., M.T.W.); Department of Pediatrics, University of Cincinnati School of Medicine, Cincinnati OH (L.J.M., K.M.K., M.K., M.T.W.); Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University, Columbus (L.C.); Herma Heart Center, Children's Hospital of Wisconsin, Milwaukee (D.W.B.); and Department of Pediatrics, Medical College of Wisconsin, Milwaukee (D.W.B.)
| | - D Woodrow Benson
- From the Department of Pediatrics, Cincinnati Children's Hospital Medical Center, OH (L.J.M., V.P., K.M.K., L.C.K., M.K., P.D., M.T.W.); Department of Pediatrics, University of Cincinnati School of Medicine, Cincinnati OH (L.J.M., K.M.K., M.K., M.T.W.); Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University, Columbus (L.C.); Herma Heart Center, Children's Hospital of Wisconsin, Milwaukee (D.W.B.); and Department of Pediatrics, Medical College of Wisconsin, Milwaukee (D.W.B.).
| |
Collapse
|
6
|
Hip geometry variation is associated with bone mineralization pathway gene variants: The Framingham Study. J Bone Miner Res 2010; 25:1564-71. [PMID: 19888898 PMCID: PMC3312740 DOI: 10.1359/jbmr.091102] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Mineralization of bone matrix is an important process in bone formation; thus defects in mineralization have been implicated in bone mineral density (BMD) and bone structure alterations. Three central regulators of phosphate balance, ALPL, ANKH, and ENPP1, are central in the matrix mineralization process; therefore, the genes encoding them are considered important candidates genes for BMD and bone geometry. To test for an association between these three candidate genes and BMD and bone geometry traits, 124 informative singlenucleotide polymorphisms (SNPs) were selected and genotyped in 1513 unrelated subjects from the Framingham offspring cohort. Initial results showed that SNP rs1974201 in the gene ENPP1 was a susceptibility variant associated with several hip geometric indices, with the strongest p value of 3.8 × 10(7) being observed for femoral neck width. A few modest associations were observed between SNPs in or near ALPL and several bone traits, but no association was observed with ANKH. The association signals observed for SNPs around rs1974201 were attenuated after conditional analysis on rs1974201. Transcription factor binding-site prediction revealed that the HOXA7 binding site was present in the reference sequence with the major allele, whereas this potential binding site is lost in the sequence with the minor allele of rs1974201. In conclusion, we found evidence for association of bone geometry variation with an SNP in ENPP1, a gene in the mineralization pathway. The alteration of a binding site of the deregulator of extracellular matrix HOXA7 warrants further investigation.
Collapse
|
7
|
Ermakov S, Toliat MR, Cohen Z, Malkin I, Altmüller J, Livshits G, Nürnberg P. Association of ALPL and ENPP1 gene polymorphisms with bone strength related skeletal traits in a Chuvashian population. Bone 2010; 46:1244-50. [PMID: 19931660 DOI: 10.1016/j.bone.2009.11.018] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/15/2009] [Revised: 10/07/2009] [Accepted: 11/13/2009] [Indexed: 10/20/2022]
Abstract
Mineralization of the extracellular matrix of bone is an essential element of bone development, maintenance and repair. ALPL and ENPP1 genes and their products are known to be central in local regulation of bone mineralization. The present study investigates potential associations of ENPP1 and ALPL polymorphisms with several phenotypes reflecting bone size and hand BMD. The study sample included 310 Caucasian nuclear families. Forty SNPs in ALPL and 14 SNPs in ENPP1 genetic loci as well as pairwise haplotypes were tested for association with bone strength related traits. Our findings suggest that the region corresponding to exons 7 through 9 of the ALPL gene harbors functional polymorphism affecting both bone size at various skeletal sites (p-value ranged from 0.01 to 0.0001) and hand bone mineral density (p-value=0.0007). The other important finding of consistent association between bone size phenotypes and the 3' untranslated region of ENPP1 gene (p-value ranged from 0.01 to 0.001) imply functional significance of this region to bone growth. The considered anthropometric and radiographic bone phenotypes are closely related to bone fragility thus suggesting a role for both genes in osteoporosis. Further research is required to validate the relevancy of the potentially functional regions identified by our and other studies to normal and pathologic bone development as well as to determine the relevancy of the polymorphisms in ALPL and ENPP1 gene loci to clinical practice.
Collapse
Affiliation(s)
- Sergey Ermakov
- Human Population Biology Research Unit, Department of Anatomy and Anthropology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | | | | | | | | | | | | |
Collapse
|
8
|
Korostishevsky M, Vistoropsky Y, Malkin I, Kobyliansky E, Livshits G. Anthropometric and bone-related biochemical factors are associated with different haplotypes of ANKH locus. Ann Hum Biol 2008; 35:535-46. [PMID: 18821330 DOI: 10.1080/03014460802304588] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
BACKGROUND The human homologue of the mouse progressive ankylosis (ANKH) gene is one of the key genetic factors involved in bone mineralization. Previous studies have shown that plasma levels of osteoprotegerin (OPG) and parathyroid hormone (PTH) are associated with the distal region of the ANKH gene, whereas skeletal size measurements are associated with the promoter region. AIM The present study examines the possible phenotype-haplotype specificity of the associations in these two gene regions. SUBJECTS AND METHODS The total sample consists of 1249 healthy individuals (mean age = 47.7, SD = 16.8) from 404 nuclear families. Fifteen interrelated anthropometric measurements were transformed into two principal components, reflecting body size and mass. Those, plus circulating levels of PTH and OPG, were subjected to association analysis, using transmission disequilibrium tests (TDTs) with ANKH gene. From 805 to 1150 individuals per SNP were genotyped. RESULTS In the proximal region (rs3006069-rs835154-rs835141), associations were found between the A-A-C haplotype and the first principal component reflecting body size (p < or = 0.048), whereas another haplotype, G-G-C, was associated with the first principal component, reflecting the body mass (p < or = 0.008). In the distal region of ANKH (rs39968-rs696294-rs875525), the A-A-C haplotype was found to be associated with OPG plasma levels (p < or = 0.001), whereas the G-A-C haplotype was associated with PTH circulating concentrations (p < or = 0.025). CONCLUSION Taken together, the results show discrimination between the corresponding regions and haplotypes, suggesting trait-specific gene variants that influenced bone-related phenotypic variation in the studied population.
Collapse
Affiliation(s)
- Michael Korostishevsky
- Human Population Biology Research Unit, Department of Anatomy and Anthropology, Tel Aviv University, Tel Aviv, Israel
| | | | | | | | | |
Collapse
|
9
|
Abstract
Crystal deposition is a very complex process ruled by numerous factors. A small but important proportion of cases of chondrocalcinosis are monogenic, and many of the genes involved have been identified. These genetic findings strongly point to control of the level of extracellular inorganic pyrophosphate as the primary mechanism for their association with either calcium pyrophosphate dihydrate or hydroxyapatite deposition. However, effects on extracellular inorganic pyrophosphate levels do not explain the mechanism of association in all of these monogenic diseases. Further, there are likely to be several as yet unidentified genes that are important in this common condition. This review highlights what genetic studies have demonstrated about the processes involved in these diverse but related disorders.
Collapse
|